Status:
TERMINATED
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Lead Sponsor:
Pfizer
Conditions:
Colorectal Neoplasms
Liver Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be perf...
Eligibility Criteria
Inclusion
- ECOG performance status of 0 or 1
- Histological documentation of adenocarcinoma of the colon or rectum. The primary site must have been confirmed to be in the large bowel
Exclusion
- Prior systemic anticancer therapy for mCRC
- Prior hepatic surgery, chemoembolization, hepatic artery infusion, radiofrequency ablation or cryotherapy for liver metastases
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00106054
Start Date
January 1 2006
End Date
September 1 2006
Last Update
August 27 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New York, New York, United States, 10029
2
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104